{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:57:20Z","timestamp":1785862640813,"version":"3.56.0"},"reference-count":64,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,3,24]],"date-time":"2013-03-24T00:00:00Z","timestamp":1364083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Exenatide once weekly is the first glucose\u2010lowering agent available to patients with type 2 diabetes mellitus (\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    ) which is administered once per week. This long\u2010acting formulation contains the same active ingredient as exenatide twice daily, except that the exenatide is encapsulated in dissolvable microspheres. Following subcutaneous injection, exenatide once weekly microspheres remain in place under the skin and slowly degrade, releasing active exenatide continuously into circulation. In randomized clinical trials, exenatide once weekly was associated with significant glycaemic improvement and moderate weight loss in patients with\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    when administered as monotherapy or in combination with a variety of oral antidiabetic agents. Exenatide once weekly also lowered blood glucose more effectively than titrated basal insulin in patients on metformin or metformin plus sulphonylurea background therapy. Gastrointestinal side effects (nausea, vomiting and diarrhoea) were the most common tolerability issues associated with exenatide once weekly administration, but they occurred at lower rates than in patients on other glucagon\u2010like peptide receptor agonists (i.e., exenatide twice daily or liraglutide). Issues regarding the place of exenatide once weekly in\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    pharmacotherapy are discussed.\n                  <\/jats:p>","DOI":"10.1111\/dom.12084","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T17:26:30Z","timestamp":1361381190000},"page":"871-881","source":"Crossref","is-referenced-by-count":24,"title":["Once weekly exenatide: efficacy, tolerability and place in therapy"],"prefix":"10.1111","volume":"15","author":[{"given":"C.","family":"Wysham","sequence":"first","affiliation":[{"name":"Department of Medicine University of Washington School of Medicine  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grimm","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, LLC  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, LLC  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)90011-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105685"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-24-10-1076"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021053"},{"issue":"3","key":"e_1_2_7_8_1","first-page":"E458","article-title":"Glucagon\u2010like peptide 1 undergoes differential tissue\u2010specific metabolism in the anesthetized pig","volume":"271","author":"Deacon CF","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.11.7143"},{"key":"e_1_2_7_10_1","unstructured":"Byetta [package insert]. San Diego CA: Amylin Pharmaceuticals LLC; 2011."},{"key":"e_1_2_7_11_1","unstructured":"Victoza [package insert]. Bagsvaerd Denmark: Novo Nordisk A\/S; 2011."},{"key":"e_1_2_7_12_1","unstructured":"Bydureon [package insert]. San Diego CA: Amylin Pharmaceuticals LLC; 2012."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.48"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01357.x"},{"key":"e_1_2_7_15_1","unstructured":"Januvia [package insert]. Whitehouse Station NJ: Merck & Co. Inc.; 2007."},{"key":"e_1_2_7_16_1","unstructured":"Onglyza [package insert]. Princeton NJ: Bristol\u2010Myers Squibb Company; 2011."},{"key":"e_1_2_7_17_1","unstructured":"Tradjenta [package insert]. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2011."},{"key":"e_1_2_7_18_1","unstructured":"European Medicines Agency. Vildagliptin: Summary of Product Characteristics. Horsham West Sussex United Kingdom: Novartis Europharm Limited; June 2012. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000771\/WC500020327.pdf. Accessed October 2012."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2243"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.08.004"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0159"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03181.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021545"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.2.173"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2146"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00030.2008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0050"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(97)00048-3"},{"key":"e_1_2_7_29_1","first-page":"1","volume-title":"Biodegradable polymers as drug delivery systems","author":"Lewis DH","year":"1990"},{"key":"e_1_2_7_30_1","unstructured":"Vivitrol [package insert]. Waltham MA: Alkermes Inc.; 2010."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585880-000000000-00000"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1107"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61267-7"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9912"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_41_1","unstructured":"AACE\/ACE Diabetes Algorithm. American Association of Clinical Endocrinologists\/American College of Endocrinology. Available from URL:http:\/\/www.aace.com\/files\/glycemic\u2010control\u2010algorithm\u2010ppt.pdf. Accessed November 2012."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03301.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1914"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-11-9"},{"key":"e_1_2_7_45_1","unstructured":"Macconell L Li Y Pencek R Schulteis C Porter L eds. Exenatide Once Weekly Resulted in Sustained Improvement in Glycemic Control with Weight Loss Through 4 Years. 72nd Scientific Session of the American Diabetes Association; Philadelphia PA June 8\u201312 2012."},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.03006.x"},{"key":"e_1_2_7_47_1","volume-title":"Efficacy and Safety of Exenatide Once Weekly Versus Exenatide Twice Daily in Asian Patients with Type 2 Diabetes","author":"Ji L","year":"2011"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2012.07.2568"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.013"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.499"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2009.05.009"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0599"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902820519"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0666"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2318"},{"key":"e_1_2_7_58_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Fast Stats 2012. Available from URL:http:\/\/seer.cancer.gov\/faststats\/. Accessed March 2012."},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721707308407"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01778.x"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.21132.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2002.10905.x"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12032"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-870529"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12084","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:08:53Z","timestamp":1761890933000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,24]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/dom.12084"],"URL":"https:\/\/doi.org\/10.1111\/dom.12084","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,24]]}}}